IDEAYA Biosciences Inc at Stifel Healthcare Conference Transcript
Yes, Ben, thanks for having us, and thanks to Stifel, for hosting us at the conference.
To start off, maybe just give a brief overview of IDEAYA, and maybe talk about your approach with synthetic lethality, just highlight near-term events that we should be paying attention to.
Yes, IDEAYA is a precision medicine oncology company with a research and development focus in synthetic lethality. Our approach to synthetic lethality is straightforward. We are focused on identifying, then executing on targets that have the potential to be first-in-class. And we think therefore the most potentially impactful for patients.
We have currently two programs that are in clinical trials, our Phase 2 Darovasertib and our early Phase 2 IDE397 targeting MAT2A. But as we look forward over the next few quarters, we will have four programs in the clinic is what we're guiding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
